Medullary thyroid cancer (MTC) is a rare type of thyroid cancer that develops from the parafollicular C cells of the thyroid gland. The medullary thyroid cancer drugs market consists of targeted therapy drugs such as Tyrosine kinase inhibitors, Somatostatin analogs and Chemotherapy drugs. These drugs play a vital role in controlling the growth of cancer cells and inhibiting their proliferation, which helps improve the survival rate of MTC patients.
The medullary thyroid cancer drugs market is estimated to be valued at USD 156 Mn in 2024 and is expected to reach USD 315 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031.
Key Takeaways
Key players operating in the medullary thyroid cancer drugs market are Pfizer, Macleods Pharmaceuticals, Baxter, Lilly and Exelixis.
The global Medullary Thyroid Cancer Drugs Market is increasing which presents lucrative opportunities for players in terms of product development, geographic expansion and partnerships. The North American region dominates the market owing to growing awareness about rare cancers.
Market Drivers
Increasing incidence of medullary thyroid cancer: According to Globocan 2020, medullary thyroid cancer accounted for 1.5% of total thyroid cancer worldwide. The rising disease burden is expected to drive the demand for targeted therapies. High unmet need: Currently only three targeted therapy drugs are approved for MTC treatment. However, these drugs do not alleviate all MTC symptoms and relapse is common. There is a strong need for more effective drugs.
Market Restraints
Limited patient pool: MTC is a rare condition with less than 1000 new cases reported annually in the US. The small patient population poses challenges for conducting large clinical trials and achieving economies of scale.
High treatment costs: Targeted drugs for MTC treatment involve high costs ranging from $10,000 to $30,000 per year. This adversely impacts treatment compliance and reimbursement scenario.
Segment Analysis
The medullary thyroid cancer drugs market is segmented based on drug type, distribution channel, and geography. By drug type, the market is segmented into caprelsa, cometriq, vandetanib, and others. The caprelsa segment dominates the medullary thyroid cancer drugs market as it was the first FDA-approved drug for treating progressive and metastatic medullary thyroid cancer and is the standard first line treatment. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominates as caprelsa and cometriq are mainly administered under medical supervision requiring hospital visits.
Global Analysis
The North America region dominates the medullary thyroid cancer drugs market. This is due to the increasing prevalence of medullary thyroid cancer in the US, availability of treatment and reimbursement coverage making the drugs affordable, and presence of key market players. The Asia Pacific region is expected to witness the highest CAGR during the forecast period owing to increasing healthcare expenditure, expansion of private hospitals capable of carrying out thyroid cancer treatment, growing awareness regarding early diagnosis, and improving access to diagnosis and treatment.
Get This Report in Japanese Language: 甲状腺髄様がん治療薬市場
Get This Report in Korean Language: 수질성 갑상선 암 약물 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
